

Technology Appraisal Committee C Interests Register

Topic: Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over [ID1494]

Publication Date: 07/06/2023

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|---------------------|----------------------|------------------|--|----------------|-------------------|-----------------|--|
| Michael Chambers | TAC Committee Member | Financial | Michael has participated in an advisory panel for Pfizer (possible comparator), in an unrelated disease area (prostate cancer). | - | 15/09/22 | - | It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal. |
| Dr Richard Nicholas | TAC Committee Member | Financial | Dr Nicholas has carried out paid advisory boards with Novartis in an unrelated area - multiple sclerosis. | - | 15/09/22 | - | It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal. |
| Stella O'Brien | TAC Committee Member | Personal | Stella is a member of the Genetics Alliance UK PPIE Working Group on ATMPs affiliated with CATAPULT cell and gene therapy to encourage the integration of PPIE throughout the research cycle from the earliest stages and onwards. CATAPULT is a network of not-for profit, independent centres which connect businesses with the UK's research and academic | - | 14/09/22 | - | It was agreed her declaration would not prevent Stella from participating in discussions on this appraisal. |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|--------------------------|----------------------|-----------------------------------|--|----------------|-------------------|-----------------|---|
| | | | communities. Although CAR-T therapies are an example of ATMPs, she has not contributed to work on CAR-T therapies with this group. | | | | |
| Professor Paul Tappenden | TAC Committee Member | Non-financial professional | Professor Tappenden works for SchARR (EAG for this topic), and he provided a peer review of the draft ERG report. | | 19/09/22 | | It was agreed that his declaration means he can contribute to the discussion but not take part in any vote. |
| Dr Deborah Yallop | Clinical expert | Direct & Indirect - non-financial | Dr Yallop has received honoraria for advisory board for Kite Gilead and Pfizer and financial support to attend meetings from Amgen, Servier, Jazz. She also provides Project support to Servier and is a principal investigator KCH AUTO-1 trial (Autolus) She has been co-investigator on the CALM trial (Servier) | | 05/11/21 | | It was agreed her declarations would not prevent Dr Yallop from providing expert advice to the committee. |
| Sophie Wheldon | Patient expert | Indirect financial | Sophie took part in a patient and carer insights workshop on CAR T with Janssen in mid-2021 and received £240. She has been diagnosed with ALL and received CAR-T therapy. She is employed by the nominating organisation Leukaemia Care who in the last 12 months received | | 18/07/22 | | It was agreed her declarations would not prevent Sophie from providing expert advice to the committee |

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|-----------------------|-----------------|------------------|---|----------------|-------------------|-----------------|---|
| | | | funding from Amgen, Incyte, Novartis, and Pfizer. | | | | |
| Professor David Marks | Clinical expert | Financial | He has been remunerated for work for Pfizer, Amgen, Novartis, and Kite in the area of ALL | | 10/01/22 | | It was agreed his declarations would not prevent Professor Marks from providing expert advice to the committee. |